RIVM recommends limiting number of e-cigarettes flavourings to 23 with tobacco taste only The government wishes to make e-cigarettes less attractive, in particular for young people.
4 in 5 COVID-19 patients in ICU are not vaccinated 4 in 5 COVID-19 patients in intensive care are not vaccinated against the coronavirus SARS-CoV-2.
Expected autumn increase in SARS-CoV-2 appears to have started In the past week from 5-12 October 2021, the reported number of people who tested positive for COVID-19 increased by 48% compared to the previous week. Reported figures increased in all regions and in all age groups.
More than health risks play a role in compliance with coronavirus measures The risk of COVID-19 is not the only factor that determines compliance with the coronavirus measures; other risks also play a role.
No evidence of more serious illness from COVID-19 among Q fever patients There are no indications that people who previously had Q fever had a more serious course of illness from the coronavirus SARS-CoV-2. This is evident from RIVM research.
Specific group of patients with impaired immunity invited in October for third COVID-19 vaccination From 6 October on, a specific group of people with severely impaired immunity (immunocompromised patients) will receive their invitation for a third vaccination against COVID-19.
Benefits and bottlenecks for early marketing authorisation of new medicines Patients are asking increasingly often for quicker access to new, innovative medicines. This requires a more effective use of flexible marketing authorisation procedures.
European Baseline Report SUSTAIN The SUSTAIN project has published the European baseline report titled ‘Integrated care for older people living at home – Current situation and ambition of sites participating in the SUSTAIN project
Particle contamination on Silimed breast implants poses minimal risk Particles were found on Silimed silicone-based breast implants that should not be there. These included man-made mineral fibres, such as glasswool and rockwool.
EFSA agrees with RIVM that potential effect of BPA on the immune system requires further attention RIVM expressed concerns on the effects of bisphenol a (BPA) on the immune system in a report issued in March 2016.